Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 36
Encontrada(s) 1 página(s)

Biblos-e Archivo. Repositorio Institucional de la UAM
Publication Tesis doctoral (DoctoralThesis)

Von Hippel-Lindau protein regulates dendritic cell activation in the thymus and periphery

  • Adán Barrientos, Irene
Tesis Doctoral inédita leída en la Universidad Autónoma de Madrid, Facultad de Medicina, Departamento de Bioquímica. Fecha de Lectura: 03-06-2025, Esta Tesis tiene embargado el acceso al texto completo hasta el 03-12-2026, La regulación de la activación de las células dendríticas (DC) es fundamental para mantener latolerancia central y periférica. En esta tesis se identifica a la proteína Von Hippel-Lindau (pVHL) como un regulador de la activación de las DCs durante la maduración homeostática e inmunogénica. Se observó que la transcripción de Vhl disminuía significativamente durante la maduración inducida por receptores tipo Toll (TLR), pero aumentaba en DCs que habían madurado de forma homeostática. Además, a pesar de que el timo se caracteriza por ser un tejidohipóxico, las DC tímicas exhibían niveles elevados de transcripción de Vhl, lo que sugiere un papel específico de pVHL en estas células. Para estudiar este fenómeno, se generó un modelo murino con depleción de Vhl en el compartimento CD11c, utilizando un sistema Cre-lox (ItgaxΔVhl). Los ratones ItgaxΔVhl presentaron una reducción del tamaño del timo y de la frecuencia de timocitos CD4+ simples positivos (CD4SP) y CD8SP. Este fenotipo se atribuyó a la estabilización de HIF1α en las DCs tímicas, ya que los ratones doble knockout ItgaxΔVhl/Hif1a mostraron un timo de tamaño normal. El análisis de los timocitos por citometría de flujo indicó una reducción de aquellos que estaban sufriendo procesos de selección negativa, como los timocitos semimaduros CD69+MHC-I− o los TCR-βhiCD5hi. También se detectó un aumento en la expresión de Nur77 y Helios (marcadores de activación del TCR) en los timocitos de los ratones ItgaxΔVhl. Además, los timocitos CD8SP mostraron menor velocidad y mayor retención en cortes histológicos de timo vivo, observados mediante microscopía multifotón, lo que sugiere una selección negativa más estricta en los ratones ItgaxΔVhl. A pesar de que la deficiencia de pVHL no afectó a la capacidad de maduración de las DCs, la disminución en el tamaño del timo sí afectó negativamente a la activación de las dendríticas de forma extrínseca. Además, la deficiencia en Vhl produjo un aumento de la presentación de antígeno celular a células OT-I y OT-I, y las cDC1 deficientes en Vhl demostraron una mayor capacidad fagocítica de restos celulares. La deficiencia de Vhl también provocó alteraciones metabólicas en cDC1 y cDC2s, volviéndolas más glucolíticas y con una menor dependencia del metabolismo mitocondrial. Mediante secuenciación de TCR se detectó que el repertorio de linfocitos CD4+ naive en ratones ItgaxΔVhl era menos diverso. En un modelo de colitis por transferencia de linfocitos CD4+CD25− de ItgaxΔVhl a ratones Rag1−/− se observó una menor pérdida de peso con respecto a la transferencia de linfocitos de ratones control, sugiriendo menor autorreactividad. Proponemos que pVHL regula la función de las DCs en el timo. En condiciones hipóxicas, pVHL es incapaz de degradar HIF1α, y de esta manera se favorece la eferocitosis y la presentaciónantigénica por parte de las DCs. Por lo tanto, la disponibilidad de oxígeno regula la activación de las DCs en el timo. Finalmente, también exploramos los efectos de la deleción de Vhl en la maduración inmunogénica de las DCs. Observamos que la estabilización de HIF1α disminuyó las moléculas de superficie y laproducción de citoquinas tras la estimulación. En conclusión, la estabilización de HIF1α aumenta la eferocitosis y la presentación antigénica durante la maduración homeostática de las dendríticas, pero regula negativamente la maduración inmunogénica tras la estimulación con TLRs, Work in the laboratory of David Sancho is funded by the CNIC; by the European Union’s Horizon 2020 research and innovation program under grant agreement ERC-2016-Consolidator Grant 725091; by MCIN PID2022-137712OB-I00, PID2019-108157RB, CPP2021-008310 and CPP2022-009762 MCIN/AEI/10.13039/501100011033 Unión Europea NextGeneration EU/PRTR; by Comunidad de Madrid (P2022/BMD-7333 INMUNOVAR-CM); by Scientific Foundation of the Spanish Association Against Cancer (AECC-PRYGN246642SANC); by Worldwide Cancer Research WWCR-25-0080; by European Union ERC-2023-PoC; by a research agreement with Inmunotek S.L.; and by “la Caixa” Foundation (LCF/PR/HR23/52430012 and LCF/PR/HR22/52420019). The CNIC is supported by the Instituto de Salud Carlos III (ISCIII), the MICIU and the Pro CNIC Foundation, and is a Severo Ochoa Centre of Excellence (CEX2020-001041-S funded by MICIU/AEI /10.13039/501100011033)
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Poststroke Lung Infection by Opportunistic Commensal Bacteria Is Not Mediated by Their Expansion in the Gut Microbiota

  • Díaz-Marugan, Laura|||0000-0002-7589-2547
  • Gallizioli, Mattia|||0000-0001-9245-914X
  • Márquez-Kisinousky, Leonardo
  • Arboleya, Silvia|||0000-0002-6155-5822
  • Mastrangelo, Annalaura|||0000-0003-2650-0444
  • Ruiz-Jaén, Francisca
  • Pedragosa, Jordi|||0000-0001-8493-4545
  • Casals-Pascual, Climent|||0000-0002-0867-8954
  • Morales, Francisco Javier
  • Ramos-Romero, Sara|||0000-0002-9293-4454
  • Traserra, Sara
  • Justicia, Carles|||0000-0003-0969-6158
  • Gueimonde, Miguel|||0000-0002-0192-901X
  • Jiménez Farrerons, Marcel|||0000-0002-6602-7332
  • Torres, Josep Lluís|||0000-0002-5072-8265
  • Urra, Xabier|||0000-0002-4763-5252
  • Chamorro, Ángel|||0000-0003-0493-5340
  • Sancho, David
  • de los Reyes-Gavilán, Clara G.|||0000-0001-9396-6311
  • Miró-Mur, Francesc|||0000-0003-3936-2693
  • Planas, Anna Maria|||0000-0002-6147-1880
Background: Respiratory and urinary tract infections are frequent complications in patients with severe stroke. Stroke-associated infection is mainly due to opportunistic commensal bacteria of the microbiota that may translocate from the gut. We investigated the mechanisms underlying gut dysbiosis and poststroke infection. Methods: Using a model of transient cerebral ischemia in mice, we explored the relationship between immunometabolic dysregulation, gut barrier dysfunction, gut microbial alterations, and bacterial colonization of organs, and we explored the effect of several drug treatments. Results: Stroke-induced lymphocytopenia and widespread colonization of lung and other organs by opportunistic commensal bacteria. This effect correlated with reduced gut epithelial barrier resistance, and a proinflammatory sway in the gut illustrated by complement and nuclear factor-κB activation, reduced number of gut regulatory T cells, and a shift of gut lymphocytes to γδT cells and T helper 1/T helper 17 phenotypes. Stroke increased conjugated bile acids in the liver but decreased bile acids and short-chain fatty acids in the gut. Gut fermenting anaerobic bacteria decreased while opportunistic facultative anaerobes, notably Enterobacteriaceae, suffered an expansion. Anti-inflammatory treatment with a nuclear factor-κB inhibitor fully abrogated the Enterobacteriaceae overgrowth in the gut microbiota induced by stroke, whereas inhibitors of the neural or humoral arms of the stress response were ineffective at the doses used in this study. Conversely, the anti-inflammatory treatment did not prevent poststroke lung colonization by Enterobacteriaceae. Conclusions: Stroke perturbs homeostatic neuro-immuno-metabolic networks facilitating a bloom of opportunistic commensals in the gut microbiota. However, this bacterial expansion in the gut does not mediate poststroke infection.
Repisalud
Publication Artículo científico (JournalArticle)

DNGR-1, a Dendritic Cell-Specific Sensor of Tissue Damage That Dually Modulates Immunity and Inflammation

  • Cueto, Francisco J.
  • del Fresno, Carlos
  • Sancho, David
DNGR-1 (encoded by CLEC9A) is a C-type lectin receptor (CLR) with an expression profile that is mainly restricted to type 1 conventional dendritic cells (cDC1s) both in mice and humans. This delimited expression pattern makes it appropriate for defining a cDC1 signature and for therapeutic targeting of this population, promoting immunity in mouse models. Functionally, DNGR-1 binds F-actin, which is confined within the intracellular space in healthy cells, but is exposed when plasma membrane integrity is compromised, as happens in necrosis. Upon F-actin binding, DNGR-1 signals through SYK and mediates cross-presentation of dead cell-associated antigens. Cross-presentation to CD8+ T cells promoted by DNGR-1 during viral infections is key for cross-priming tissue-resident memory precursors in the lymph node. However, in contrast to other closely related CLRs such as Dectin-1, DNGR-1 does not activate NFκB. Instead, recent findings show that DNGR-1 can activate SHP-1 to limit inflammation triggered by heterologous receptors, which results in reduced production of inflammatory chemokines and neutrophil recruitment into damaged tissues in both sterile and infectious processes. Hence, DNGR-1 reduces immunopathology associated with tissue damage, promoting disease tolerance to safeguard tissue integrity. How DNGR-1 signals are conditioned by the microenvironment and the detailed molecular mechanisms underlying DNGR-1 function have not been elucidated. Here, we review the expression pattern and structural features of DNGR-1, and the biological relevance of the detection of tissue damage through this CLR.
Repisalud
Publication Artículo científico (JournalArticle)

Cell death induced by cytotoxic CD8+ T cells is immunogenic and primes caspase-3-dependent spread immunity against endogenous tumor antigens

  • Jaime-Sanchez, Paula
  • Uranga-Murillo, Iratxe
  • Aguilo, Nacho
  • Khouili, Sofia C.
  • Arias, Maykel A
  • Sancho, David
  • Pardo, Julian
BACKGROUND: Elimination of cancer cells by some stimuli like chemotherapy and radiotherapy activates anticancer immunity after the generation of damage-associated molecular patterns, a process recently named immunogenic cell death (ICD). Despite the recent advances in cancer immunotherapy, very little is known about the immunological consequences of cell death activated by cytotoxic CD8+ T (Tc) cells on cancer cells, that is, if Tc cells induce ICD on cancer cells and the molecular mechanisms involved. METHODS: ICD induced by Tc cells on EL4 cells was analyzed in tumor by vaccinating mice with EL4 cells killed in vitro or in vivo by Ag-specific Tc cells. EL4 cells and mutants thereof overexpressing Bcl-XL or a dominant negative mutant of caspase-3 and wild-type mice, as well as mice depleted of Tc cells and mice deficient in perforin, TLR4 and BATF3 were used. Ex vivo cytotoxicity of spleen cells from immunized mice was analyzed by flow cytometry. Expression of ICD signals (calreticulin, HMGB1 and interleukin (IL)-1β) was analyzed by flow cytometry and ELISA. RESULTS: Mice immunized with EL4.gp33 cells killed in vitro or in vivo by gp33-specific Tc cells were protected from parental EL4 tumor development. This result was confirmed in vivo by using ovalbumin (OVA) as another surrogate antigen. Perforin and TLR4 and BATF3-dependent type 1 conventional dendritic cells (cDC1s) were required for protection against tumor development, indicating cross-priming of Tc cells against endogenous EL4 tumor antigens. Tc cells induced ICD signals in EL4 cells. Notably, ICD of EL4 cells was dependent on caspase-3 activity, with reduced antitumor immunity generated by caspase-3-deficient EL4 cells. In contrast, overexpression of Bcl-XL in EL4 cells had no effect on induction of Tc cell antitumor response and protection. CONCLUSIONS: Elimination of tumor cells by Ag-specific Tc cells is immunogenic and protects against tumor development by generating new Tc cells against EL4 endogenous antigens. This finding helps to explain the enhanced efficacy of T cell-dependent immunotherapy and provide a molecular basis to explain the epitope spread phenomenon observed during vaccination and chimeric antigen receptor (CAR)-T cell therapy. In addition, they suggest that caspase-3 activity in the tumor may be used as a biomarker to predict cancer recurrence during T cell-dependent immunotherapies.
Repisalud
Publication Artículo científico (JournalArticle)

Dendritic cells in cancer immunology and immunotherapy

  • Wculek, Stefanie K
  • Cueto, Francisco J.
  • Mujal, Adriana M
  • Melero, Ignacio
  • Krummel, Matthew F
  • Sancho, David
Dendritic cells (DCs) are a diverse group of specialized antigen-presenting cells with key roles in the initiation and regulation of innate and adaptive immune responses. As such, there is currently much interest in modulating DC function to improve cancer immunotherapy. Many strategies have been developed to target DCs in cancer, such as the administration of antigens with immunomodulators that mobilize and activate endogenous DCs, as well as the generation of DC-based vaccines. A better understanding of the diversity and functions of DC subsets and of how these are shaped by the tumour microenvironment could lead to improved therapies for cancer. Here we will outline how different DC subsets influence immunity and tolerance in cancer settings and discuss the implications for both established cancer treatments and novel immunotherapy strategies.
Repisalud
Publication Artículo científico (JournalArticle)

Dendritic Cells and Microglia Have Non-redundant Functions in the Inflamed Brain with Protective Effects of Type 1 cDCs

  • Gallizioli, Mattia
  • Miró-Mur, Francesc
  • Otxoa-de-Amezaga, Amaia
  • Cugota, Roger
  • Salas-Perdomo, Angélica
  • Justicia, Carles
  • Brait, Vanessa H
  • Ruiz-Jaén, Francisca
  • Arbaizar-Rovirosa, Maria
  • Pedragosa, Jordi
  • Bonfill-Teixidor, Ester
  • Gelderblom, Mathias
  • Magnus, Tim
  • Cano, Eva
  • del Fresno, Carlos
  • Sancho, David
  • Planas, Anna M
Brain CD11c+ cells share features with microglia and dendritic cells (DCs). Sterile inflammation increases brain CD11c+ cells, but their phenotype, origin, and functions remain largely unknown. We report that, after cerebral ischemia, microglia attract DCs to the inflamed brain, and astroglia produce Flt3 ligand, supporting development and expansion of CD11c+ cells. CD11c+ cells in the inflamed brain are a complex population derived from proliferating microglia and infiltrating DCs, including a major subset of OX40L+ conventional cDC2, and also cDC1, plasmacytoid, and monocyte-derived DCs. Despite sharing certain morphological features and markers, CD11c+ microglia and DCs display differential expression of pattern recognition receptors and chemokine receptors. DCs excel CD11c- and CD11c+ microglia in the capacity to present antigen through MHCI and MHCII. Of note, cDC1s protect from brain injury after ischemia. We thus reveal aspects of the dynamics and functions of brain DCs in the regulation of inflammation and immunity.
Repisalud
Publication Artículo científico (JournalArticle)

Clec2d Joins the Cell Death Sensor Ranks

  • del Fresno, Carlos
  • Sancho, David
Sensing tissue damage is an ancient function of immune cells that is central to the regulation of inflammation, tissue repair, and immunity. In this issue of Immunity, Lai et al. (2020) uncover a role for the C-type lectin receptor Clec2d as a sensor of cell death, which directly detects histones released during necrosis and thus contributes to inflammation and immunopathology.
Repisalud
Publication Artículo científico (JournalArticle)

Targeting SHIP-1 in Myeloid Cells Enhances Trained Immunity and Boosts Response to Infection

  • Saz-Leal, Paula
  • del Fresno, Carlos
  • Brandi, Paola
  • Martinez-Cano, Sarai
  • Dungan, Otto M.
  • Chisholm, John D.
  • Kerr, William G.
  • Sancho, David
beta-Glucan-induced trained immunity in myeloid cells leads to long-term protection against secondary infections. Although previous studies have characterized this phenomenon, strategies to boost trained immunity remain undefined. We found that beta-glucan-trained macrophages from mice with a myeloid-specific deletion of the phosphatase SHIP-1 (LysM Delta SHIP-1) showed enhanced proinflammatory cytokine production in response to lipopolysaccharide. Following beta-glucan training, SHIP-1-deficient macrophages exhibited increased phosphorylation of Akt and mTOR targets, correlating with augmented glycolytic metabolism. Enhanced training in the absence of SHIP-1 relied on histone methylation and acetylation. Trained LysM Delta SHIP-1 mice produced increased amounts of proinflammatory cytokines upon rechallenge in vivo and were better protected against Candida albicans infection compared with control littermates. Pharmacological inhibition of SHIP-1 enhanced trained immunity against Candida infection in mouse macrophages and human peripheral blood mononuclear cells. Our data establish proof of concept for improvement of trained immunity and a strategy to achieve it by targeting SHIP-1.
Repisalud
Publication Artículo científico (JournalArticle)

The Flt3L/Flt3 Axis in Dendritic Cell Biology and Cancer Immunotherapy.

  • Cueto, Francisco J.
  • Sancho, David
Dendritic cells (DCs) prime anti-tumor T cell responses in tumor-draining lymph nodes and can restimulate T effector responses in the tumor site. Thus, in addition to unleashing T cell effector activity, current immunotherapies should be directed to boost DC function. Herein, we review the potential function of Flt3L as a tool for cancer immunotherapy. Flt3L is a growth factor that acts in Flt3-expressing multipotent progenitors and common lymphoid progenitors. Despite the broad expression of Flt3 in the hematopoietic progenitors, the main effect of the Flt3/Flt3L axis, revealed by the characterization of mice deficient in these genes, is the generation of conventional DCs (cDCs) and plasmacytoid DCs (pDCs). However, Flt3 signaling through PI3K and mTOR may also affect the function of mature DCs. We recapitulate the use of Flt3L in preclinical studies either as a single agent or in combination with other cancer therapies. We also analyze the use of Flt3L in clinical trials. The strong correlation between type 1 cDC (cDC1) infiltration of human cancers with overall survival in many cancer types suggests the potential use of Flt3L to boost expansion of this DC subset. However, this may need the combination of Flt3L with other immunomodulatory agents to boost cancer immunotherapy.
Repisalud
Publication Artículo científico (JournalArticle)

The Bacterial Mucosal Immunotherapy MV130 Protects Against SARS-CoV-2 Infection and Improves COVID-19 Vaccines Immunogenicity.

  • Del Fresno, Carlos
  • García-Arriaza, Juan
  • Martínez-Cano, Sarai
  • Heras-Murillo, Ignacio
  • Jarit-Cabanillas, Aitor
  • Amores-Iniesta, Joaquin
  • Brandi, Paola
  • Dunphy, Gillian
  • Suay-Corredera, Carmen
  • Pricolo, Maria Rosaria
  • Vicente, Natalia
  • López-Perrote, Andrés
  • Cabezudo, Sofía
  • González-Corpas, Ana
  • Llorca, Oscar
  • Alegre-Cebollada, Jorge
  • Garaigorta, Urtzi
  • Gastaminza, Pablo
  • Esteban, Mariano
  • Sancho, David
COVID-19-specific vaccines are efficient prophylactic weapons against SARS-CoV-2 virus. However, boosting innate responses may represent an innovative way to immediately fight future emerging viral infections or boost vaccines. MV130 is a mucosal immunotherapy, based on a mixture of whole heat-inactivated bacteria, that has shown clinical efficacy against recurrent viral respiratory infections. Herein, we show that the prophylactic intranasal administration of this immunotherapy confers heterologous protection against SARS-CoV-2 infection in susceptible K18-hACE2 mice. Furthermore, in C57BL/6 mice, prophylactic administration of MV130 improves the immunogenicity of two different COVID-19 vaccine formulations targeting the SARS-CoV-2 spike (S) protein, inoculated either intramuscularly or intranasally. Independently of the vaccine candidate and vaccination route used, intranasal prophylaxis with MV130 boosted S-specific responses, including CD8+-T cell activation and the production of S-specific mucosal IgA antibodies. Therefore, the bacterial mucosal immunotherapy MV130 protects against SARS-CoV-2 infection and improves COVID-19 vaccines immunogenicity.
Repisalud
Publication Artículo científico (JournalArticle)

Genealogy, Dendritic Cell Priming, and Differentiation of Tissue-esident Memory CD8(+) T Cells

  • Enamorado, Michel
  • Khouili, Sofia C.
  • Iborra, Salvador
  • Sancho, David
Tissue-resident memory CD8(+) T (Trm) cells define a distinct non-recirculating subset. Trm cells constitute a first line of defense against local infections in barrier tissues, but they are also found in non-barrier tissues and play a role in antitumor immunity. Their differentiation in tissues and their phenotypical, transcriptional, and functional characteristics are the object of active research. Herein, we will discuss the potential existence of committed CD8(+) Trm precursors and the genealogy of memory CD8(+) T cell subsets. In addition to the priming of naive T cells, there is some plasticity of antigen-experienced effector and memory T cell subsets to generate Trm precursors. Local inflammation, antigen presentation, and cytokines drive Trm differentiation. It is of prime interest how specific dendritic cell subsets modulate priming and differentiation of Trm cells, as well as their reactivation within tissues. Research on how we can manipulate generation of memory T cells subsets is key for improved vaccination strategies.
Repisalud
Publication Artículo científico (JournalArticle)

Mitochondrial response to fever boosts T1-driven inflammatory responses.

  • Dunphy, Gillian
  • Sancho, David
Increased body temperature, both locally and systemically, is a key feature of the inflammatory response. Heat is associated with increased blood flow to affected areas and increased immune infiltrate, yet increased temperature has also been described to have direct effects on immune cell function. In a recent study, Heintzman, et al investigated the effect of febrile temperature (39 °C) on T cell function. They describe increased T1 function and fitness accompanied by a decrease in regulatory T cell suppressive function. These findings add another important consequence to our understanding of fever responses.
Repisalud
Publication Artículo científico (JournalArticle)

Distinct Compartmentalization of the Chemokines CXCL1 and CXCL2 and the Atypical Receptor ACKR1 Determine Discrete Stages of Neutrophil Diapedesis

  • Girbl, Tamara
  • Lenn, Tchern
  • Perez, Lorena
  • Rolas, Loïc
  • Barkaway, Anna
  • Thiriot, Aude
  • del Fresno, Carlos
  • Lynam, Eleanor
  • Hub, Elin
  • Thelen, Marcus
  • Graham, Gerard
  • Alon, Ronen
  • Sancho, David
  • von Andrian, Ulrich H
  • Voisin, Mathieu-Benoit
  • Rot, Antal
  • Nourshargh, Sussan
Neutrophils require directional cues to navigate through the complex structure of venular walls and into inflamed tissues. Here we applied confocal intravital microscopy to analyze neutrophil emigration in cytokine-stimulated mouse cremaster muscles. We identified differential and non-redundant roles for the chemokines CXCL1 and CXCL2, governed by their distinct cellular sources. CXCL1 was produced mainly by TNF-stimulated endothelial cells (ECs) and pericytes and supported luminal and sub-EC neutrophil crawling. Conversely, neutrophils were the main producers of CXCL2, and this chemokine was critical for correct breaching of endothelial junctions. This pro-migratory activity of CXCL2 depended on the atypical chemokine receptor 1 (ACKR1), which is enriched within endothelial junctions. Transmigrating neutrophils promoted a self-guided migration response through EC junctions, creating a junctional chemokine "depot" in the form of ACKR1-presented CXCL2 that enabled efficient unidirectional luminal-to-abluminal migration. Thus, CXCL1 and CXCL2 act in a sequential manner to guide neutrophils through venular walls as governed by their distinct cellular sources.
Repisalud
Publication Artículo científico (JournalArticle)

Metabolism of tissue macrophages in homeostasis and pathology.

  • Wculek, Stefanie K
  • Dunphy, Gillian
  • Heras-Murillo, Ignacio
  • Mastrangelo, Annalaura
  • Sancho, David
Cellular metabolism orchestrates the intricate use of tissue fuels for catabolism and anabolism to generate cellular energy and structural components. The emerging field of immunometabolism highlights the importance of cellular metabolism for the maintenance and activities of immune cells. Macrophages are embryo- or adult bone marrow-derived leukocytes that are key for healthy tissue homeostasis but can also contribute to pathologies such as metabolic syndrome, atherosclerosis, fibrosis or cancer. Macrophage metabolism has largely been studied in vitro. However, different organs contain diverse macrophage populations that specialize in distinct and often tissue-specific functions. This context specificity creates diverging metabolic challenges for tissue macrophage populations to fulfill their homeostatic roles in their particular microenvironment and conditions their response in pathological conditions. Here, we outline current knowledge on the metabolic requirements and adaptations of macrophages located in tissues during homeostasis and selected diseases.
Repisalud
Publication Artículo científico (JournalArticle)

cDC1s: New Orchestrators of Tissue Innate Immunity

  • del Fresno, Carlos
  • Sancho, David
Type-I conventional dendritic cells (cDC1s) are key in inducing adaptive immunity. Using single-cell sequencing, Ginhoux and colleagues (Immunity 2019;50:1069-1083.e8) find that a subset of activated cDC1s in bacteria-infected skin is critical for neutrophil recruitment via the production of VEGF-α. These results reveal a crucial function for cDC1s beyond antigen presentation.
Repisalud
Publication Artículo científico (JournalArticle)

Flexible Signaling of Myeloid C-Type Lectin Receptors in Immunity and Inflammation

  • del Fresno, Carlos
  • Iborra, Salvador
  • Saz-Leal, Paula
  • Martinez-Lopez, Maria
  • Sancho, David
Myeloid C-type lectin receptors (CLRs) are important sensors of self and non-self that work in concert with other pattern recognition receptors (PRRs). CLRs have been previously classified based on their signaling motifs as activating or inhibitory receptors. However, specific features of the ligand binding process may result in distinct signaling through a single motif, resulting in the triggering of non-canonical pathways. In addition, CLR ligands are frequently exposed in complex structures that simultaneously bind different CLRs and other PRRs, which lead to integration of heterologous signaling among diverse receptors. Herein, we will review how sensing by myeloid CLRs and crosstalk with heterologous receptors is modulated by many factors affecting their signaling and resulting in differential outcomes for immunity and inflammation. Finding common features among those flexible responses initiated by diverse CLR-ligand partners will help to harness CLR function in immunity and inflammation.
Repisalud
Publication Tesis doctoral (DoctoralThesis)

Role of SHIP-1 phosphatase in trained immunity modulation

  • Sanz-Leal, Paula
β-glucan-induced trained immunity in monocytes confers long-term protection against secondary infections through activation of the dendritic cell-associated C-type lectin 1 (Dectin-1)/ Phosphoinositide 3-kinase (PI3K)/ mammalian target of rapamycin (mTOR) pathway. While previous studies have addressed the characterization of this phenomenon, strategies to boost trained immunity deserve further investigation. Src homology 2 (SH2) domain-containing inositol 5'-phosphatase (SHIP)-1 is a hematopoietic-restricted phosphatase that limits PI3K activity and it is able to associate with Dectin-1 receptor. Therefore, we hypothesized that SHIP-1 targeting could modulate trained immunity mediated by Dectin-1 ligands.Herein, we found that β-glucan-trained macrophages from mice with a myeloidspecific SHIP-1 deletion (LysMΔSHIP-1) enhanced proinflammatory cytokine production in response to lipopolysaccharide (LPS). Following β-glucan training, SHIP1-deficient macrophages exhibited increased phosphorylation of protein kinase B (also known as Akt, a downstream target of PI3K), and mTOR targets. These overactivation of the signaling pathway correlated with augmented glycolytic metabolism. Furthermore, enhanced training in the absence of SHIP-1 relied on epigenetic reprogramming, including histone methylation and acetylation. Trained LysMΔSHIP-1 mice produced increased proinflammatory cytokines upon rechallenge in vivo and were better protected against systemic Candida albicans infection compared with control littermates. Pharmacological inhibition of SHIP-1 enhanced trained immunity in vitro in mouse macrophages and human peripheral blood mononuclear cells (hPBMCs), and also improved protection conferred by immune training with C. albicans. These data establish a proof of concept for improvement of trained immunity, and place SHIP-1 as a target to achieve it.
Repisalud
Publication Artículo científico (JournalArticle)

Microbiota Sensing by Mincle-Syk Axis in Dendritic Cells Regulates Interleukin-17 and -22 Production and Promotes Intestinal Barrier Integrity

  • Martinez-Lopez, Maria
  • Iborra, Salvador
  • Conde-Garrosa, Ruth
  • Mastrangelo, Annalaura
  • Danne, Camille
  • Mann, Elizabeth R
  • Reid, Delyth M
  • Gaboriau-Routhiau, Valérie
  • Chaparro, Maria
  • Lorenzo, María P
  • Minnerup, Lara
  • Saz-Leal, Paula
  • Slack, Emma
  • Kemp, Benjamin
  • Gisbert, Javier P
  • Dzionek, Andrzej
  • Robinson, Matthew J
  • Rupérez, Francisco J
  • Cerf-Bensussan, Nadine
  • Brown, Gordon D
  • Bernardo, David
  • LeibundGut-Landmann, Salomé
  • Sancho, David
Production of interleukin-17 (IL-17) and IL-22 by T helper 17 (Th17) cells and group 3 innate lymphoid cells (ILC3s) in response to the gut microbiota ensures maintenance of intestinal barrier function. Here, we examined the mechanisms whereby the immune system detects microbiota in the steady state. A Syk-kinase-coupled signaling pathway in dendritic cells (DCs) was critical for commensal-dependent production of IL-17 and IL-22 by CD4+ T cells. The Syk-coupled C-type lectin receptor Mincle detected mucosal-resident commensals in the Peyer's patches (PPs), triggered IL-6 and IL-23p19 expression, and thereby regulated function of intestinal Th17- and IL-17-secreting ILCs. Mice deficient in Mincle or with selective depletion of Syk in CD11c+ cells had impaired production of intestinal RegIIIγ and IgA and increased systemic translocation of gut microbiota. Consequently, Mincle deficiency led to liver inflammation and deregulated lipid metabolism. Thus, sensing of commensals by Mincle and Syk signaling in CD11c+ cells reinforces intestinal immune barrier and promotes host-microbiota mutualism, preventing systemic inflammation.
Repisalud
Publication Artículo científico (JournalArticle)

Dectin-1/2-induced autocrine PGE(2) signaling licenses dendritic cells to prime Th2 responses

  • Kaiser, Maria M. M.
  • Ritter, Manuel
  • del Fresno, Carlos
  • Jonesdottir, Hulda S.
  • van der Ham, Alwin J.
  • Pelgrom, Leonard R.
  • Schramm, Gabriele
  • Leyland, Laura E.
  • Sancho, David
  • da Costa, Clarissa Prazeres
  • Giere, Martin
  • Yazdanbakhsh, Maria
  • Everts, Bart
The molecular mechanisms through which dendritic cells (DCs) prime T helper 2 (Th2) responses, including those elicited by parasitic helminths, remain incompletely understood. Here, we report that soluble egg antigen (SEA) from Schistosoma mansoni, which is well known to drive potent Th2 responses, triggers DCs to produce prostaglandin E2 (PGE(2)), which subsequently-in an autocrine manner-induces OX40 ligand (OX40L) expression to license these DCs to drive Th2 responses. Mechanistically, SEA was found to promote PGE(2) synthesis through Dectin-1 and Dectin-2, and via a downstream signaling cascade involving spleen tyrosine kinase (Syk), extracellular signal-regulated kinase (ERK), cytosolic phospholipase A(2) (cPLA(2)), and cyclooxygenase 1 and 2 (COX-1 and COX-2). In addition, this pathway was activated independently of the actions of omega-1 (omega-1), a previously described Th2-priming glycoprotein present in SEA. These findings were supported by in vivo murine data showing that w-1 independent Th2 priming by SEA was mediated by Dectin-2 and Syk signaling in DCs. Finally, we found that Dectin-2(-/-), and to a lesser extent Dectin-1(-/-) mice, displayed impaired Th2 responses and reduced egg-driven granuloma formation following S. mansoni infection, highlighting the physiological importance of this pathway in Th2 polarization during a helminth infection. In summary, we identified a novel pathway in DCs involving Dectin-1/2-Syk-PGE(2)-OX40L through which Th2 immune responses are induced.
Repisalud
Publication Artículo científico (JournalArticle)

Sensing Tissue Damage by Myeloid C-Type Lectin Receptors

  • del Fresno, Carlos
  • Cueto, Francisco J.
  • Sancho, David
After both sterile and infectious insults, damage is inflicted on tissues leading to accidental or programmed cell death. In addition, events of programmed cell death also take place under homeostatic conditions, such as in embryo development or in the turnover of hematopoietic cells. Mammalian tissues are seeded with myeloid immune cells, which harbor a plethora of receptors that allow the detection of cell death, modulating immune responses. The myeloid C-type lectin receptors (CLRs) are one of the most prominent families of receptors involved in tailoring immunity after sensing dead cells. In this chapter, we will cover a diversity of signals arising from different forms of cell death and how they are recognized by myeloid CLRs. We will also explore how myeloid cells develop their sentinel function, exploring how some of these CLRs identify cell death and the type of responses triggered thereof. In particular, we will focus on DNGR-1 (CLEC9A), Mincle (CLEC4E), CLL-1 (CLEC12A), LOX-1 (OLR1), CD301 (CLEC10A) and DEC-205 (LY75) as paradigmatic death-sensing CLRs expressed by myeloid cells. The molecular processes triggered after cell death recognition by myeloid CLRs contribute to the regulation of immune responses in pathologies associated with tissue damage, such as infection, autoimmunity and cancer. A better understanding of these processes may help to improve the current approaches for therapeutic intervention.
Repisalud
Publication Artículo científico (JournalArticle)

Metabolic Control of Dendritic Cell Functions: Digesting Information

  • Wculek, Stefanie K
  • Khouili, Sofia C.
  • Priego, Elena
  • Heras-Murillo, Ignacio
  • Sancho, David
Dendritic cells (DCs) control innate and adaptive immunity by patrolling tissues to gather antigens and danger signals derived from microbes and tissue. Subsequently, DCs integrate those environmental cues, orchestrate immunity or tolerance, and regulate tissue homeostasis. Recent advances in the field of immunometabolism highlight the notion that immune cells markedly alter cellular metabolic pathways during differentiation or upon activation, which has important implications on their functionality. Previous studies showed that active oxidative phosphorylation in mitochondria is associated with immature or tolerogenic DCs, while increased glycolysis upon pathogen sensing can promote immunogenic DC functions. However, new results in the last years suggest that regulation of DC metabolism in steady state, after immunogenic activation and during tolerance in different pathophysiological settings, may be more complex. Moreover, ontogenically distinct DC subsets show different functional specializations to control T cell responses. It is, thus, relevant how metabolism influences DC differentiation and plasticity, and what potential metabolic differences exist among DC subsets. Better understanding of the emerging connection between metabolic adaptions and functional DC specification will likely allow the development of therapeutic strategies to manipulate immune responses.
Repisalud
Publication Artículo científico (JournalArticle)

A Neutrophil Timer Coordinates Immune Defense and Vascular Protection

  • Adrover, Jose M
  • del Fresno, Carlos
  • Crainiciuc, Georgiana
  • Cuartero, Maria Isabel
  • Casanova-Acebes, Maria
  • Weiss, Linnea A
  • Huerga-Encabo, Hector
  • Silvestre-Roig, Carlos
  • Rossaint, Jan
  • Cossio, Itziar
  • Lechuga-Vieco, Ana V.
  • Garcia-Prieto, Jaime
  • Gomez-Parrizas, Monica
  • Quintana, Juan A.
  • Ballesteros, Ivan
  • Martin-Salamanca, Sandra
  • Aroca-Crevillen, Alejandra
  • Chong, Shu Zhen
  • Evrard, Maximilien
  • Balabanian, Karl
  • López, Jorge
  • Bidzhekov, Kiril
  • Bachelerie, Françoise
  • Abad-Santos, Francisco
  • Muñoz-Calleja, Cecilia
  • Zarbock, Alexander
  • Soehnlein, Oliver
  • Weber, Christian
  • Ng, Lai Guan
  • Lopez-Rodriguez, Cristina
  • Sancho, David
  • Moro, Maria Angeles
  • Ibáñez, Borja
  • Hidalgo, Andres
Neutrophils eliminate pathogens efficiently but can inflict severe damage to the host if they over-activate within blood vessels. It is unclear how immunity solves the dilemma of mounting an efficient anti-microbial defense while preserving vascular health. Here, we identify a neutrophil-intrinsic program that enabled both. The gene Bmal1 regulated expression of the chemokine CXCL2 to induce chemokine receptor CXCR2-dependent diurnal changes in the transcriptional and migratory properties of circulating neutrophils. These diurnal alterations, referred to as neutrophil aging, were antagonized by CXCR4 (C-X-C chemokine receptor type 4) and regulated the outer topology of neutrophils to favor homeostatic egress from blood vessels at night, resulting in boosted anti-microbial activity in tissues. Mice engineered for constitutive neutrophil aging became resistant to infection, but the persistence of intravascular aged neutrophils predisposed them to thrombo-inflammation and death. Thus, diurnal compartmentalization of neutrophils, driven by an internal timer, coordinates immune defense and vascular protection.
Repisalud
Publication Artículo científico (JournalArticle)

Leishmania Hijacks Myeloid Cells for Immune Escape

  • Martinez-Lopez, Maria
  • Soto, Manuel
  • Iborra, Salvador
  • Sancho, David
Protozoan parasites of the Leishmania genus are the causative agents of leishmaniasis, a group of neglected tropical diseases whose clinical manifestations vary depending on the infectious Leishmania species but also on host factors. Recognition of the parasite by host myeloid immune cells is a key to trigger an effective Leishmania-specific immunity. However, the parasite is able to persist in host myeloid cells by evading, delaying and manipulating host immunity in order to escape host resistance and ensure its transmission. Neutrophils are first in infiltrating infection sites and could act either favoring or protecting against infection, depending on factors such as the genetic background of the host or the parasite species. Macrophages are the main host cells where the parasites grow and divide. However, macrophages are also the main effector population involved in parasite clearance. Parasite elimination by macrophages requires the priming and development of an effector Th1 adaptive immunity driven by specific subtypes of dendritic cells. Herein, we will provide a comprehensive outline of how myeloid cells regulate innate and adaptive immunity against Leishmania, and the mechanisms used by the parasites to promote their evasion and sabotage. Understanding the interactions between Leishmania and the host myeloid cells may lead to the development of new therapeutic approaches and improved vaccination to leishmaniases, an important worldwide health problem in which current therapeutic or preventive approaches are limited.
Repisalud
Publication Artículo científico (JournalArticle)

Functional CD169 on Macrophages Mediates Interaction with Dendritic Cells for CD8(+) T Cell Cross-Priming

  • van Dinther, Dieke
  • Veninga, Henrike
  • Iborra, Salvador
  • Borg, Ellen G. F.
  • Hoogterp, Leoni
  • Olesek, Katarzyna
  • Beijer, Marieke R.
  • Schetters, Sjoerd T. T.
  • Kalay, Hakan
  • Garcia-Vallejo, Juan J.
  • Franken, Kees L.
  • Cham, Lamin B.
  • Lang, Karl S.
  • van Kooyk, Yvette
  • Sancho, David
  • Crocker, Paul R.
  • den Haan, Joke M. M.
Splenic CD169(+) macrophages are located in the marginal zone to efficiently capture blood-borne pathogens. Here, we investigate the requirements for the induction of CD8(+) T cell responses by antigens (Ags) bound by CD169(+) macrophages. Upon Ag targeting to CD169(+) macrophages, we show that BATF3-dependent CD8 alpha(+) dendritic cells (DCs) are crucial for DNGR-1-mediated cross-priming of CD8(+) T cell responses. In addition, we demonstrate that CD169, a sialic acid binding lectin involved in cell-cell contact, preferentially binds to CD8 alpha(+) DCs and that Ag transfer to CD8 alpha(+) DCs and subsequent T cell activation is dependent on the sialic acid-binding capacity of CD169. Finally, functional CD169 mediates optimal CD8(+) T cell responses to modified vaccinia Ankara virus infection. Together, these data indicate that the collaboration of CD169(+) macrophages and CD8 alpha(+) DCs for the initiation of effective CD8(+) T cell responses is facilitated by binding of CD169 to sialic acid containing ligands on CD8 alpha(+) DCs.
Repisalud
Publication Artículo científico (JournalArticle)

DNGR-1 limits Flt3L-mediated antitumor immunity by restraining tumor-infiltrating type I conventional dendritic cells.

  • Cueto, Francisco J
  • Del Fresno, Carlos
  • Brandi, Paola
  • Combes, Alexis J
  • Hernández-García, Elena
  • Sánchez-Paulete, Alfonso R
  • Enamorado, Michel
  • Bromley, Christian P
  • Gomez, Manuel J
  • Conde-Garrosa, Ruth
  • Mañes, Santos
  • Zelenay, Santiago
  • Melero, Ignacio
  • Iborra, Salvador
  • Krummel, Matthew F
  • Sancho, David
Conventional type 1 dendritic cells (cDC1s) are central to antitumor immunity and their presence in the tumor microenvironment associates with improved outcomes in patients with cancer. DNGR-1 (CLEC9A) is a dead cell-sensing receptor highly restricted to cDC1s. DNGR-1 has been involved in both cross-presentation of dead cell-associated antigens and processes of disease tolerance, but its role in antitumor immunity has not been clarified yet. B16 and MC38 tumor cell lines were inoculated subcutaneously into wild-type (WT) and DNGR-1-deficient mice. To overexpress Flt3L systemically, we performed gene therapy through the hydrodynamic injection of an Flt3L-encoding plasmid. To characterize the immune response, we performed flow cytometry and RNA-Seq of tumor-infiltrating cDC1s. Here, we found that cross-presentation of tumor antigens in the steady state was DNGR-1-independent. However, on Flt3L systemic overexpression, tumor growth was delayed in DNGR-1-deficient mice compared with WT mice. Of note, this protection was recapitulated by anti-DNGR-1-blocking antibodies in mice following Flt3L gene therapy. This improved antitumor immunity was associated with Batf3-dependent enhanced accumulation of CD8+ T cells and cDC1s within tumors. Mechanistically, the deficiency in DNGR-1 boosted an Flt3L-induced specific inflammatory gene signature in cDC1s, including Ccl5 expression. Indeed, the increased infiltration of cDC1s within tumors and their protective effect rely on CCL5/CCR5 chemoattraction. Moreover, FLT3LG and CCL5 or CCR5 gene expression signatures correlate with an enhanced cDC1 signature and a favorable overall survival in patients with cancer. Notably, cyclophosphamide elevated serum Flt3L levels and, in combination with the absence of DNGR-1, synergized against tumor growth. DNGR-1 limits the accumulation of tumor-infiltrating cDC1s promoted by Flt3L. Thus, DNGR-1 blockade may improve antitumor immunity in tumor therapy settings associated to high Flt3L expression.
Repisalud
Publication Artículo científico (JournalArticle)

Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen

  • Wculek, Stefanie K
  • Amores-Iniesta, Joaquin
  • Conde-Garrosa, Ruth
  • Khouili, Sofia C.
  • Melero, Ignacio
  • Sancho, David
BACKGROUND: The manipulation of dendritic cells (DCs) for cancer vaccination has not reached its full potential, despite the revolution in cancer immunotherapy. DCs are fundamental for CD8+ T cell activation, which relies on cross-presentation of exogenous antigen on MHC-I and can be fostered by immunogenic cancer cell death. Translational and clinical research has focused on in vitro-generated monocyte-derived DCs, while the vaccination efficacy of natural conventional type 1 DCs (cDC1s), which are associated with improved anti-tumor immunity and specialize on antigen cross-presentation, remains unknown. METHODS: We isolated primary spleen mouse cDC1s and established a protocol for fast ex vivo activation and antigen-loading with lysates of tumor cells that underwent immunogenic cell death by UV irradiation. Natural tumor antigen-loaded cDC1s were transferred and their potential for induction of endogenous CD8+ and CD4+ T cell responses in vivo, cancer prevention and therapy were assessed in three grafted cancer models. Further, we tested the efficacy of natural cDC1 vaccination in combination and comparison with anti-PD-1 treatment in two "wildtype" tumor models not expressing exogenous antigens. RESULTS: Herein, we reveal that primary mouse cDC1s ex vivo loaded with dead tumor cell-derived antigen are activated and induce strong CD8+ T cell responses from the endogenous repertoire upon adoptive transfer in vivo through tumor antigen cross-presentation. Notably, cDC1-based vaccines enhance tumor infiltration by cancer-reactive CD8+ and CD4+ T cells and halt progression of engrafted cancer models, including tumors that are refractory to anti-PD-1 treatment. Moreover, combined tumor antigen-loaded primary cDC1 and anti-PD-1 therapy had strong synergistic effects in a PD-1 checkpoint inhibition susceptible cancer model. CONCLUSIONS: This preclinical proof-of-principle study is first to support the therapeutic efficacy of cancer immunotherapy with syngeneic dead tumor cell antigen-loaded mouse cDC1s, the equivalents of the human dendritic cell subset that correlates with beneficial prognosis of cancer patients. Our data pave the way for translation of cDC1-based cancer treatments into the clinic when isolation of natural human cDC1s becomes feasible.
Repisalud
Publication Artículo científico (JournalArticle)

A Proposal for Nomenclature in Myeloid C-Type Lectin Receptors

  • del Fresno, Carlos
  • Cueto, Francisco J.
  • Sancho, David
Myeloid C-type lectin receptors (CLRs) comprise a family of receptors expressed by immune myeloid cells that share homologous C-type lectin domains. The implication of these CLRs in the regulation of homeostasis and activation of myeloid cells has generated a buoyant growth in the number of studies involving these receptors. Since their first description, diverse nomenclature has been used to refer to each of them, ranging from systematic classifications, such as gene name or cluster of differentiation, to non-systematic ones that include terminology based on gene expression patterns or function. In this review, we aim to summarize the different names used for the main myeloidCLRs and analyzewhich of themhave beenmore frequently used in the literature. In addition, we have examined the evolution of the terminology applied to these myeloid CLRs over time. Based on this analysis, we propose a consensus alias for each of those myeloid CLRs. However, we acknowledge that systematicity is required beyond this terminology based on use frequency. Therefore, we have included gene names as the standardization tool to gather the maximum agreement. We suggest that a standard nomenclature consisting of both gene names and consensus alias should be included at least in scientific abstracts, which would help to identify relevant literature, saving time and effort and fostering the research in this field in a more systematic manner.
Repisalud
Publication Artículo científico (JournalArticle)

Von Hippel-Lindau Protein Is Required for Optimal Alveolar Macrophage Terminal Differentiation, Self-Renewal, and Function

  • Izquierdo-Fernandez, Helena Maria
  • Brandi, Paola
  • Gomez, Manuel J
  • Conde-Garrosa, Ruth
  • Priego, Elena
  • Enamorado, Michel
  • Martinez-Cano, Sarai
  • Sanchez, Iris
  • Conejero, Laura
  • Jimenez-Carretero, Daniel
  • Martin-Puig, Silvia
  • Guilliams, Martin
  • Sancho, David
The rapid transit from hypoxia to normoxia in the lung that follows the first breath in newborn mice coincides with alveolar macrophage (AM) differentiation. However, whether sensing of oxygen affects AM maturation and function has not been previously explored. We have generated mice whose AMs show a deficient ability to sense oxygen after birth by deleting Vhl, a negative regulator of HIF transcription factors, in the CD11c compartment (CD11c Delta Vhl mice). VHL-deficient AMs show an immature-like phenotype and an impaired self-renewal capacity in vivo that persists upon culture ex vivo. VHL-deficient phenotype is intrinsic in AMs derived from monocyte precursors in mixed bone marrow chimeras. Moreover, unlike control Vhl(fl/fl), AMs from CD11c Delta Vhl mice do not reverse pulmonary alveolar proteinosis when transplanted into Csf2rb(-/)(-) mice, demonstrating that VHL contributes to AM-mediated surfactant clearance. Thus, our results suggest that optimal AM terminal differentiation, self-renewal, and homeostatic function requires their intact oxygen-sensing capacity.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Dendritic Cells and Microglia Have Non-redundant Functions in the Inflamed Brain with Protective Effects of Type 1 cDCs

  • Gallizioli, Mattia
  • Miró-Mur, Francesc
  • Otxoa de Amezaga, Amaia
  • Cugota, Roger
  • Salas-Perdomo, Angélica
  • Justicia, Carles
  • Brait, Vanessa
  • Ruíz-Jaén, Francisca
  • Arbaizar-Rovirosa, María
  • Pedragosa, Jordi
  • Bonfill-Teixidor, Ester
  • Gelderblom, Mathias
  • Magnus, Tim
  • Cano, Eva
  • Fresno, Carlos del
  • Sancho, David
  • Planas, Anna M.
CD11c dendritic cells infiltrate the brain after ischemic injury and share some features with microglia. Gallizioli et al. show that dendritic cells exhibit a transcriptional profile different from microglia and excel in antigen presentation. Microglia attract different DC subsets via chemokines, especially cDC1 that exert beneficial functions in cerebral ischemia.Brain CD11c cells share features with microglia and dendritic cells (DCs). Sterile inflammation increases brain CD11c cells, but their phenotype, origin, and functions remain largely unknown. We report that, after cerebral ischemia, microglia attract DCs to the inflamed brain, and astroglia produce Flt3 ligand, supporting development and expansion of CD11c cells. CD11c cells in the inflamed brain are a complex population derived from proliferating microglia and infiltrating DCs, including a major subset of OX40L conventional cDC2, and also cDC1, plasmacytoid, and monocyte-derived DCs. Despite sharing certain morphological features and markers, CD11c microglia and DCs display differential expression of pattern recognition receptors and chemokine receptors. DCs excel CD11c and CD11c microglia in the capacity to present antigen through MHCI and MHCII. Of note, cDC1s protect from brain injury after ischemia. We thus reveal aspects of the dynamics and functions of brain DCs in the regulation of inflammation and immunity., This work was funded by Ministerio de Ciencia, Innovación y Universidades (MICINN) co-financed by Fondo Europeo de Desarrollo Regional (FEDER) ( SAF2017-87459-R ), the European Union (EU) ( H2020-ITN-2018-813294-ENTRAIN ), and Fundació Marató TV3 ( 201723 to A.M.P. and D.S.). Work in the D.S. laboratory is funded by Centro Nacional de Investigaciones Cardiovasculares (CNIC), the European Research Council (ERC-2016-Consolidator Grant 725091 ), the EU ( 635122-PROCROP H2020 ), and MICINN-FEDER ( SAF2016-79040-R ). The EU ( FP7-PEOPLE-2013-ITN-n°07962 ) supported M. Gallizioli. The PERIS program of Generalitat de Catalunya supported F.M.-M. A.O.-d.-A. had a fellowship from MICINN-FPI ( BES-2015-074419 ). C.d.F. is supported by the AECC Foundation ( INVES192DELF ). We thank Anaxomics, the genomics and informatics BioCore Units of Centre for Genomic Regulation, the Cytomics and Experimental 7T MRI platforms of IDIBAPS, and the Advanced Optical Microscopy Unit-CCiT of the University of Barcelona for technical support. We thank Dr. U. Perpiñá for microscopy assistance. Plexxikon Inc. provided PLX5622 under a materials transfer agreement. Part of this work was performed at Centre de Recerca Biomèdica Cellex. The Centres de Recerca de Catalunya (CERCA) Program of Generalitat de Catalunya supports IDIBAPS.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Fgr kinase is required for proinflammatory macrophage activation during diet-induced obesity

  • Acín-Pérez, Rebeca
  • Iborra, Salvador
  • Martí-Mateos, Yolanda
  • Cook, Emma C. L.
  • Conde-Garrosa, Ruth
  • Petcherski, Anton
  • Muñoz, María del Mar
  • Martínez de Mena, Raquel
  • Krishnan, Karthickeyan Chella
  • Jiménez, Concepción
  • Bolaños, Juan P.
  • Laakso, Markku
  • Lusis, Aldons J.
  • Shirihai, Orian S.
  • Sancho, David
  • Enríquez, José Antonio
Proinflammatory macrophages are key in the development of obesity. In addition, reactive oxygen species (ROS), which activate the Fgr tyrosine kinase, also contribute to obesity. Here we show that ablation of Fgr impairs proinflammatory macrophage polarization while preventing high-fat diet (HFD)-induced obesity in mice. Systemic ablation of Fgr increases lipolysis and liver fatty acid oxidation, thereby avoiding steatosis. Knockout of Fgr in bone marrow (BM)-derived cells is sufficient to protect against insulin resistance and liver steatosis following HFD feeding, while the transfer of Fgr-expressing BM-derived cells reverts protection from HFD feeding in Fgr-deficient hosts. Scavenging of mitochondrial peroxides is sufficient to prevent Fgr activation in BM-derived cells and HFD-induced obesity. Moreover, Fgr expression is higher in proinflammatory macrophages and correlates with obesity traits in both mice and humans. Thus, our findings reveal the mitochondrial ROS–Fgr kinase as a key regulatory axis in proinflammatory adipose tissue macrophage activation, diet-induced obesity, insulin resistance and liver steatosis., The METSIM study was supported by grants from the Academy of Finland (no. 321428), Sigrid Juselius Foundation, Finnish Foundation for Cardiovascular Research, Centre of Excellence of Cardiovascular and Metabolic Diseases and the Academy of Finland (to M.L.). Work in the laboratory of J.A.E. is funded by the CNIC and a grant by Ministerio de Ciencia, Innovación e Universidades (MICINN), Agencia Estatal de Investigación (AEI) and Fondo Europeo de Desarrollo Regional (FEDER; SAF2015-65633-R and RTI2018-099357-B-I00), the EU (UE0/MCA317433), the Biomedical Research Networking Center on Frailty and Healthy Ageing (CIBERFES-ISCiii) and the HFSP agency (RGP0016/2018). Work in the laboratory of D.S. is funded by the CNIC; the European Research Council (ERC-2016-Consolidator Grant 725091); the European Commission (635122-PROCROP H2020); MICINN, AEI and FEDER (SAF2016-79040-R and PID2019-108157RB); Comunidad de Madrid (B2017/BMD-3733 Immunothercan-CM); FIS-Instituto de Salud Carlos III, MICINN and FEDER (RD16/0015/0018-REEM); the Acteria Foundation; Atresmedia (Constantes y Vitales prize); and Fundació La Marató de TV3 (201723). Work in the laboratory of O.S.S. is funded by National Institutes of Health (NIH; R01 DK099618-05, R01 CA232056-01, R21AG060456-01 and R21 AG063373-01) and the American Diabetes Association (1-19-IBS-049). Work in laboratory of A.J.L. was supported by NIH-PO1HL028481 and NIH-R01DK117850 (A.J.L.). Work in the laboratory of M.L. was funded by the Academy of Finland. Work in the laboratory of J.P.B. was funded by Spanish Ministry of Science, Innovation and Universities (MCINU/FEDER; grants SAF2016-78114-R and RED2018‐102576‐T), Instituto de Salud Carlos III (CB16/10/00282), Junta de Castilla y León (Escalera de Excelencia CLU-2017-03), Ayudas Equipos Investigación Biomedicina 2017 Fundación BBVA and Fundación Ramón Areces. The CNIC is supported by the Instituto de Salud Carlos III (ISCIII), MICINN and the Pro CNIC Foundation and is a Severo Ochoa Center of Excellence (SEV-2015-0505). K.C.K. is funded by NIH-K99 DK120875 and AHA Fellowship 18POST33990256. S.I. is funded by RYC-2016-19463 and RTI2018-094484-B-I00.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Poststroke Lung Infection by Opportunistic Commensal Bacteria Is Not Mediated by Their Expansion in the Gut Microbiota

  • Díaz-Marugan, Laura
  • Gallizioli, Mattia
  • Márquez-Kisinousky, Leonardo
  • Arboleya, Silvia
  • Mastrangelo, Annalaura
  • Ruiz-Jaén, Francisca
  • Pedragosa, Jordi
  • Casals, Climent
  • Morales, Francisco Javier
  • Ramos-Romero, Sara
  • Traserra, Sara
  • Justicia, Carles
  • Gueimonde Fernández, Miguel
  • Jiménez, Marcel
  • Torres, Josep Lluís
  • Urra, Xabier
  • Chamorro, Ángel
  • Sancho, David
  • González de los Reyes-Gavilán, Clara
  • Miró-Mur, Francesc
  • Planas, Anna M.
Respiratory and urinary tract infections are frequent complications in patients with severe stroke. Stroke-associated infection is mainly due to opportunistic commensal bacteria of the microbiota that may translocate from the gut. We investigated the mechanisms underlying gut dysbiosis and poststroke infection., Funded by Fundació la Marató de TV3 (ref. 201723-30-31-32) to Drs Planas, Urra, and Sancho; the Ministerio de Ciencia e Innovación (MICINN)/AEI/10.13039/501100011033 and European Regional Development Fund (ERDF) A way of making Europe by the European Union (PID2020-113202RB-I00 to Dr Planas); CSIC Interdisciplinary Thematic Platform Plataforma Temática Interdisciplinar (PTI)+Neuro-Aging of the Consejo Superior de Investigaciones Científicas (Dr Planas) funded M. Gallizioli. The work of Instituto de Productos Lácteos (IPLA)-Consejo Superior de Investigaciones Científicas (CSIC) group was partly financed by grant AYUD/2021/ 50981 from Principality of Asturias. The work of Institut de Química Avançada de Catalunya (IQAC)-CSIC was financed by Ministerio de Economía y Competitividad (AGL2017-83599-R) and MICINN (PID2020-117009RB-I00). Dr Díaz-Marugan was funded by La Caixa Foundation (ID 100010434; code LCF/BQ/DE16/11570021). Dr Arboleya received a postdoctoral Juan de la Cierva contract (MICINN, Ref. IJCI-2017-32156). Work in Dr Sancho laboratory was funded by Centro de Investigaciones Cardiovasculares (CNIC), European Union’s Horizon 2020 research and innovation program under grant agreement ERC-2016-Consolidator Grant 725091, and MICINN (PID2019-108157RB/AEI/10.13039/501100011033)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Dendritic Cell-Mediated Cross-Priming by a Bispecific Neutralizing Antibody Boosts Cytotoxic T Cell Responses and Protects Mice against SARS-CoV-2

  • Lázaro-Gorines, Rodrigo
  • Pérez Ramírez, Patricia
  • Heras-Murillo, Ignacio
  • Adán-Barrientos, Irene
  • Albericio, Guillermo
  • Astorgano, David
  • Flores, Sara
  • Luczkowiak, Joanna
  • Labiod, Nuria
  • Harwood, Seandean Lykke
  • Segura-Tudela, Alejandro
  • Rubio-Pérez, Laura
  • Nugraha, Yudhi
  • Shang, Xiaoran
  • Li, Yuxing
  • Alfonso, Carlos
  • Adipietro, Kaylin A.
  • Abeyawardhane, Dinendra L.
  • Navarro, Rocío
  • Compte, Marta
  • Yu, Wenbo
  • MacKerell Jr., Alexander D.
  • Sanz, Laura
  • Weber, David J.
  • Blanco, Francisco J.
  • Esteban, Mariano
  • Pozharski, Edwin
  • Godoy-Ruiz, Raquel
  • Muñoz, Inés G.
  • Delgado, Rafael
  • Sancho, David
  • García-Arriaza, Juan
  • Álvarez-Vallina, Luis
17 p.-4 fig., Administration of neutralizing antibodies (nAbs) has proved to be effective by providing immediate protection against SARS-CoV-2. However, dual strategies combining virus neutralization and immune response stimulation to enhance specific cytotoxic T cell responses, such as dendritic cell (DC) cross-priming, represent a promising field but have not yet been explored. Here, a broadly nAb, TNT, are first generated by grafting an anti-RBD biparatopic tandem nanobody onto a trimerbody scaffold. Cryo-EM data show that the TNT structure allows simultaneous binding to all six RBD epitopes, demonstrating a high-avidity neutralizing interaction. Then, by C-terminal fusion of an anti-DNGR-1 scFv to TNT, the bispecific trimerbody TNTDNGR-1 is generated to target neutralized virions to type 1 conventional DCs (cDC1s) and promote T cell cross-priming. Therapeutic administration of TNTDNGR-1, but not TNT, protects K18-hACE2 mice from a lethal SARS-CoV-2 infection, boosting virus-specific humoral responses and CD8+ T cell responses. These results further strengthen the central role of interactions with immune cells in the virus-neutralizing antibody activity and demonstrate the therapeutic potential of the Fc-free strategy that can be used advantageously to provide both immediate and long-term protection against SARS-CoV-2 and other viral infections., SARS-CoV-2 B.1.351 and B.1.167.2 viruses used in this study were obtained through the European Virus Archive Global (EVA-GLOBAL) project that has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 653316. SARS-CoV-2 B.1 (MAD6 isolate) was kindly provided by José M. Honrubia and Luis Enjuanes (CNB-CSIC, Madrid, Spain). The authors thank Centro de Investigación en Sanidad Animal (CISA)-Instituto Nacional de Investigaciones Agrarias (INIA-CSIC) (Valdeolmos, Madrid, Spain) for the BSL-3 facilities. Research in LA-V laboratory was funded by the BBVA Foundation (Ayudas Fundación BBVA a Equipos de Investigación Científica SARS-CoV-2 y COVID-19); the MCIN/AEI/10.13039/501100011033 (PID2020-117323RB-I00 and PDC2021-121711-I00), partially supported by the European Regional Development Fund (ERDF); the Carlos III Health Institute (ISCIII) (DTS20/00089), partially supported by the ERDF, the Spanish Association Against Cancer (AECC 19084); the CRIS Cancer Foundation (FCRIS-IFI-2018 and FCRIS-2021-0090), the Fundación Caixa-Health Research (HR21-00761 project IL7R_LungCan), and the Comunidad de Madrid (P2022/BMD-7225 NEXT_GEN_CART_MAD-CM). Work in the DS laboratory was funded by the CNIC; the European Union's Horizon 2020 research and innovation program under grant agreement ERC-2016-Consolidator Grant 725091; MCIN/AEI/10.13039/501100011033 (PID2019-108157RB); Comunidad de Madrid (B2017/BMD-3733 Immunothercan-CM); Atresmedia (Constantes y Vitales prize); Fondo Solidario Juntos (Banco Santander); and “La Caixa” Foundation (LCF/PR/HR20/00075). The CNIC was supported by the ISCIII, the MCIN and the Pro CNIC Foundation and is a Severo Ochoa Center of Excellence (CEX2020-001041-S funded by MCIN/AEI/10.13039/501100011033). Research in RD laboratory was supported by the ISCIII (PI2100989) and CIBERINFEC; the European Commission Horizon 2020 Framework Programme (grant numbers 731868 project VIRUSCAN FETPROACT-2016, and 101046084 project EPIC-CROWN-2); and the Fundación Caixa-Health Research (grant number HR18-00469 project StopEbola). Research in CNB-CSIC laboratory was funded by Fondo Supera COVID-19 (Crue Universidades-Banco Santander) grant, CIBERINFEC, and Spanish Research Council (CSIC) grant 202120E079 (to J.G.-A.), CSIC grant 2020E84 (to M.E.), MCIN/AEI/10.13039/501100011033 (PID2020-114481RB-I00 to J.G-A. and M.E.), and by the European Commission-NextGenerationEU, through CSIC's Global Health Platform (PTI Salud Global) to J.G.-A. and M.E. Work in the CIB-CSIC laboratory was supported by MCIN/AEI/10.13039/501100011033 (PID2019-104544GB-I00 and 2023AEP105 to CA, and PID2020-113225GB-I00 to F.J.B.). Cryo-EM data were collected at the Maryland Center for Advanced Molecular Analyses which was supported by MPOWER (The University of Maryland Strategic Partnership). I.H.-M. receives the support of a fellowship from la Caixa Foundation (ID 100010434, fellowship code: LCF/BQ/IN17/11620074) and from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement no. 71367. L.R.-P. was supported by a predoctoral fellowship from the Immunology Chair, Universidad Francisco de Vitoria/Merck., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Imidazole propionate is a driver and therapeutic target in atherosclerosis

  • Mastrangelo, Annalaura
  • Robles-Vera, Iñaki
  • Mañanes, Diego
  • Galán, Miguel
  • Femenía-Muiña, Marcos
  • Redondo-Urzainqui, Ana
  • Barrero-Rodríguez, Rafael
  • Papaioannou, Eleftheria
  • Amores-Iniesta, Joaquín
  • Devesa, Ana
  • Lobo-González, Manuel
  • Carreras, Alba
  • Beck, Katharina R.
  • Ivarsson, Sophie
  • Gummesson, Anders
  • Georgiopoulos, Georgios
  • Rodrigo-Tapias, Manuel
  • Martínez-Cano, Sarai
  • Fernández-López, Ivan
  • Nuñez, Vanessa
  • Ferrarini, Alessia
  • Inohara, Naohiro
  • Stamatelopoulos, Kimon
  • Benguría, Alberto
  • Cibrian, Danay
  • Sánchez-Madrid, Francisco
  • Alonso-Herranz, Vanesa
  • Dopazo, Ana
  • Barbas, Coral
  • Vázquez, Jesús
  • López, Juan Antonio
  • González-Martín, Alicia
  • Nuñez, Gabriel
  • Stellos, Konstantinos
  • Bergström, Göran
  • Bäckhed, Fredrik
  • Fuster, Valentín
  • Ibañez, Borja
  • Sancho, David
Atherosclerosis is the main underlying cause of cardiovascular diseases. Its prevention is based on the detection and treatment of traditional cardiovascular risk factors1. However, individuals at risk for early vascular disease often remain unidentified2. Recent research has identified new molecules in the pathophysiology of atherosclerosis3, highlighting the need for alternative disease biomarkers and therapeutic targets to improve early diagnosis and therapy efficacy. Here, we observed that imidazole propionate (ImP), produced by microorganisms, is associated with the extent of atherosclerosis in mice and in two independent human cohorts. Furthermore, ImP administration to atherosclerosis-prone mice fed with chow diet was sufficient to induce atherosclerosis without altering the lipid profile, and was linked to activation of both systemic and local innate and adaptive immunity and inflammation. Specifically, we found that ImP caused atherosclerosis through the imidazoline-1 receptor (I1R, also known as nischarin) in myeloid cells. Blocking this ImP–I1R axis inhibited the development of atherosclerosis induced by ImP or high-cholesterol diet in mice. Identification of the strong association of ImP with active atherosclerosis and the contribution of the ImP–I1R axis to disease progression opens new avenues for improving the early diagnosis and personalized therapy of atherosclerosis., M. O. Garmendia for assistance with the metadata from volunteers; members of the D.S. laboratory for help with discussions and critical reading of the manuscript; and the CNIC facilities, foremost the animal, cellomics, histology, metabolomics, genomics, microscopy, clinical trial and bioinformatics facilities, and personnel for assistance. I.R.-V. is funded by FJC2021-048099-I funded by MCIN/AEI/10.13039/501100011033 and European Union NextGenerationEU/PRTR. D.M. is funded by grant PRE2020-092578 MCIN/AEI/10.13039/501100011033. M.G. is funded by beca de formación de profesorado Universitario fellowship 20/01418. M.F.-M. is funded by INPhINIT Retaining 2024 from Caixa Foundation LCF/BQ/DR24/12080010. A.R.-U. is supported by Community of Madrid (PIPF-2022/SALGL-24581). R.B.-R. is funded by Beca de Formación de Profesorado Universitario Fellowship 20/03365. A. Devesa is scientifically supported by the Thrasher Research Fund and acknowledges the support of Sociedad Española de Cardiología (grant SEC/PRS-MOV-INT20/002). Work in the D.S. laboratory is funded by the CNIC; the European Union’s Horizon 2020 Research and Innovation Program under grant agreement ERC-2016-Consolidator Grant 725091; Ministerio de Ciencia, Innovación y Universidades (MICIU) PID2022-137712OB-I00, CPP2021-008310 and CPP2022-009762 MICIU/AEI/10.13039/501100011033 Agencia Estatal de Investigación, Unión Europea NextGenerationEU/PRTR; Comunidad de Madrid (P2022/BMD-7333 INMUNOVAR-CM); Scientific Foundation of the Spanish Association Against Cancer (AECC- PRYGN246642SANC); Worldwide Cancer Research WWCR-25-0080; European Union ERC-2023-PoC; a research agreement with Inmunotek S.L.; and la Caixa Foundation (LCF/PR/HR23/52430012 and LCF/PR/HR22/52420019). Work in the B.I. laboratory is supported by the European Commission (H2020-HEALTH 945118 and ERC-CoG 819775); the PID2022-140176OB-I00, PID2019-107332RB-I00 MCIN/AEI /10.13039/501100011033; and the Comunidad de Madrid RENIM P2022/BMD-7403. F.B. is funded by grants from the Swedish Heart Lung Foundation (20240882) and is a Wallenberg Fellow and recipient of an ERC-Advanced grant 2022 (101096705-IMPACT). K. Stellos was supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation — Project ID 394046768 — SFB1366 ‘Vascular control of organ function’ C07), the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (MODVASC, grant agreement 759248), the German Centre for Cardiovascular Research (DZHK) and the Helmholtz-Institute for Translational AngioCardioScience (HI-TAC) of the Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC) at Heidelberg University, Heidelberg, Germany. Metabolomics Workbench is supported by NIH grant U2C-DK119886 and OT2-OD030544 grants. The CNIC is supported by the Instituto de Salud Carlos III (ISCIII), the MICIU and the Pro CNIC Foundation, and is a Severo Ochoa Center of Excellence (CEX2020-001041-S funded by MICIU/AEI /10.13039/501100011033). The PESA study is funded by the CNIC and Santander Bank. This study was partially funded by an intramural grant CNIC-Severo Ochoa to B.I. and D.S., With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2020-001041-S), Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Cell death induced by cytotoxic CD8 + T cells is immunogenic and primes caspase-3-dependent spread immunity against endogenous tumor antigens

  • Jaime-Sanchez, Paula
  • Uranga-Murillo, Iratxe
  • Aguilo, Nacho
  • Khouili, Sofía C.
  • Arias, Maykel A.
  • Sancho, David
  • Pardo, Julián
Background Elimination of cancer cells by some stimuli like chemotherapy and radiotherapy activates anticancer immunity after the generation of damage-associated molecular patterns, a process recently named immunogenic cell death (ICD). Despite the recent advances in cancer immunotherapy, very little is known about the immunological consequences of cell death activated by cytotoxic CD8 + T (Tc) cells on cancer cells, that is, if Tc cells induce ICD on cancer cells and the molecular mechanisms involved. Methods ICD induced by Tc cells on EL4 cells was analyzed in tumor by vaccinating mice with EL4 cells killed in vitro or in vivo by Ag-specific Tc cells. EL4 cells and mutants thereof overexpressing Bcl-X L or a dominant negative mutant of caspase-3 and wild-type mice, as well as mice depleted of Tc cells and mice deficient in perforin, TLR4 and BATF3 were used. Ex vivo cytotoxicity of spleen cells from immunized mice was analyzed by flow cytometry. Expression of ICD signals (calreticulin, HMGB1 and interleukin (IL)-1ß) was analyzed by flow cytometry and ELISA. Results Mice immunized with EL4.gp33 cells killed in vitro or in vivo by gp33-specific Tc cells were protected from parental EL4 tumor development. This result was confirmed in vivo by using ovalbumin (OVA) as another surrogate antigen. Perforin and TLR4 and BATF3-dependent type 1 conventional dendritic cells (cDC1s) were required for protection against tumor development, indicating cross-priming of Tc cells against endogenous EL4 tumor antigens. Tc cells induced ICD signals in EL4 cells. Notably, ICD of EL4 cells was dependent on caspase-3 activity, with reduced antitumor immunity generated by caspase-3-deficient EL4 cells. In contrast, overexpression of Bcl-X L in EL4 cells had no effect on induction of Tc cell antitumor response and protection. Conclusions Elimination of tumor cells by Ag-specific Tc cells is immunogenic and protects against tumor development by generating new Tc cells against EL4 endogenous antigens. This finding helps to explain the enhanced efficacy of T cell-dependent immunotherapy and provide a molecular basis to explain the epitope spread phenomenon observed during vaccination and chimeric antigen receptor (CAR)-T cell therapy. In addition, they suggest that caspase-3 activity in the tumor may be used as a biomarker to predict cancer recurrence during T cell-dependent immunotherapies.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Intravenous administration of BCG in mice promotes natural killer and T cell-mediated antitumor immunity in the lung

  • Moreo, Eduardo
  • Jarit-Cabanillas, Aitor
  • Robles-Vera, Iñaki
  • Uranga, Santiago
  • Guerrero, Claudia
  • Gómez, Ana Belén
  • Mata-Martínez, Pablo
  • Minute, Luna
  • Araujo-Voces, Miguel
  • Felgueres, María José
  • Esteso, Gloria
  • Uranga-Murillo, Iratxe
  • Arias, Maykel
  • Pardo, Julián
  • Martín, Carlos
  • Valés-Gómez, Mar
  • del Fresno, Carlos
  • Sancho, David
  • Aguiló, Nacho
Intravesical administration of Bacillus Calmette-Guérin (BCG) was one of the first FDA-approved immunotherapies and remains a standard treatment for bladder cancer. Previous studies have demonstrated that intravenous (IV) administration of BCG is well-tolerated and effective in preventing tuberculosis infection in animals. Here, we examine IV BCG in several preclinical lung tumor models. Our findings demonstrate that BCG inoculation reduced tumor growth and prolonged mouse survival in models of lung melanoma metastasis and orthotopic lung adenocarcinoma. Moreover, IV BCG treatment was well-tolerated with no apparent signs of acute toxicity. Mechanistically, IV BCG induced tumor-specific CD8+ T cell responses, which were dependent on type 1 conventional dendritic cells, as well as NK cell-mediated immunity. Lastly, we also show that IV BCG has an additive effect on anti-PD-L1 checkpoint inhibitor treatment in mouse lung tumors that are otherwise resistant to anti-PD-L1 as monotherapy. Overall, our study demonstrates the potential of systemic IV BCG administration in the treatment of lung tumors, highlighting its ability to enhance immune responses and augment immune checkpoint blockade efficacy.
RUO. Repositorio Institucional de la Universidad de Oviedo
Publication Artículo científico (JournalArticle)

Intravenous administration of bcg in mice promotes natural killer and t cell-mediated antitumor immunity in the lung

  • Moreo, E.
  • Jarit Cabanillas, A.
  • Robles Vera, I.
  • Araujo Voces, Miguel|||0000-0003-3360-4479
This work was supported by MCIN/AEI/10.13039/501100011033 [grants number RTI2018-097625-B-I00 and PID2022-138624OB-I00], Gobierno de Aragón [grant number LMP50_21] and Asociación Española Contra el Cáncer (AECC) [grant number IDEAS211042AGUI]. NA was the principal investigator of all these grants. This research was supported by CIBER -Consorcio Centro de Investigación Biomédica en Red- (Groups CB06/06/0020 and CB21/13/00087), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea – European Regional Development Fund. DS laboratory is funded by the CNIC; by the European Union’s Horizon 2020 research and innovation program under grant agreement ERC-2016-Consolidator Grant 725091; by MCIN PID2019-108157RB MCIN/AEI/10.13039/501100011033 and CPP2021-008310 MCIN/AEI/10.13039/501100011033 Unión Europea Next GenerationEU/PRTR; by Comunidad de Madrid (P2022/BMD-7333 INMUNOVAR-CM); and by “la Caixa” Foundation (LCF/PR/HR20/00075 and LCF/PR/HR22/00253).The laboratory of C.d.F. is funded by Instituto de Salud Carlos III (ISCIII) through the projects CP20/00106 and PI21/01178 and co-funded by the European Union. The laboratory of M.V-G. is funded by Spanish Ministry of Science and Innovation [grant number PID2021-123795OB-I00]., Moreo E., Jarit-Cabanillas A., Robles-Vera I., Uranga S., Guerrero C., Gómez A.B., Mata-Martínez P., Minute L., Araujo-Voces M., Felgueres M.J., Esteso G., Uranga-Murillo I., Arias M., Pardo J., Martín C., Valés-Gómez M., del Fresno C., Sancho D., Aguiló N.